

Tuesday, 2 September 2025

9:30 am - 10:00 am	Badge Collection & Coffee ⓘ
10:00 am - 10:05 am	Introduction ⓘ
10:05 am - 10:30 am	An overview of new treatment options in AML ⓘ
10:30 am - 10:55 am	Using epigenetic regulators in AML ⓘ
10:55 am - 11:20 am	CLL and BiTEs (Bispecific T-cell engagers) ⓘ
11:20 am - 11:45 am	Break ⓘ
11:45 am - 12:10 pm	ALLtogether trial – ALL in infants, children and young adults ⓘ
12:10 pm - 12:25 pm	Discussion & Q&A ⓘ
12:25 pm - 1:10 pm	Industry Satellite Symposium ⓘ
1:10 pm - 1:55 pm	Lunch ⓘ
1:55 pm - 2:20 pm	Management of central nervous system leukemia ⓘ
2:20 pm - 2:45 pm	Antibody therapy and lymphoma trials ⓘ
2:45 pm - 3:10 pm	The future of CAR-T therapy ⓘ
3:10 pm - 3:25 pm	Discussion & Q&A ⓘ
3:25 pm - 3:50 pm	Break ⓘ
3:50 pm - 4:15 pm	CAR-T cell therapy to treat T-cell acute lymphoblastic leukaemia (T-ALL) ⓘ
4:15 pm - 4:40 pm	

Allogeneic haematopoietic stem cell transplantation and gene therapy

4:40 pm - 5:05 pm	Personalised therapies in multiple myeloma ⓘ
5:05 pm - 5:20 pm	Discussion & Q&A ⓘ
5:20 pm	Close & 1hr Networking Reception ⓘ